Which Parkinson’s Disease treatments are approved for patients?


Parkinson's Disease Market

Parkinson’s Disease is a debilitating disease that is caused by degeneration of nerve cells in the brain known as the substantia nigra that controls movement. 

The present Parkinson’s disease treatment options that are given to the patients include medication, complementary and supportive therapies (such as diet, exercise, physical therapy, occupational therapy, and speech therapy), and surgery. The approved medication therapies are categorized into seven groups that include Levodopa, Carbidopa-levodopa infusion (Duodopa), Dopamine agonists (Mirapex, Requip, Neupro), MAO B inhibitors (Zelapar, Azilect, Xadago), Catechol O-methyltransferase (COMT) inhibitors (Tasmar, Comtan), Anticholinergics (Cogentin, Artane), and Amantadine.  

The treatment with monoamine oxidase-B (MAO-B) inhibitors, amantadine (Symmetrel), or anticholinergics may modestly improve mild symptoms; however, most patients need levodopa or a dopamine agonist. The most frequently prescribed combination drugs are carbidopa/levodopa (cocareldopa [sinemet, pharmacopa, atamet]) and benserazide/levodopa (co-beneldopa [Madopar]). More recently, continuous intestinal infusion of levodopa gel (Duodopa [AbbVie Limited]) has shown to be effective in terms of decreasing severe motor fluctuations when compared to oral levodopa. However, this treatment is currently prohibitively expensive for widespread use. Levodopa with a DOPA decarboxylase inhibitor is usually a first-line
Parkinson’s disease treatment option.   

For patients with advanced Parkinson’s Disease, most surgeries are preferred. Most of the Parkinson’s disease treatments are aimed at helping the tremor or rigidity that comes with the Disease.  

Several approved therapies drive the current Parkinson’s Disease therapeutic landscape in the US. The available Parkinson’s Disease therapeutics options aim to offer significant symptomatic relief of the motor and non-motor symptoms.

There are many pharmaceutical and biotech companies like Prevail Therapeutics, Axovant Gene Therapies, Neurocrine Biosciences/Voyager Therapeutics, Denali Therapeutics that are researching new therapies to target other aspects of pathology, namely genetic mutations, and Lewy bodies (a hallmark feature of Parkinson’s Disease).

Of  Parkinson’s Disease emerging therapies, the most anticipated product to get launched is VY-ADCC (Voyager Therapeutics). Apart from this, other products include Istradefylline (Kyowa Kirin), Opicapone (Neurocrine Biosciences), P2B001 (Pharma Two B Ltd), LY03003 (Luye Pharma), ABBV-951 (AbbVie), APL-130277 (Sunovion Pharma), Accordion Pill (Intec Pharma).


Comments

  1. UnknownFebruary 28, 2020 at 8:39 AM

    Did you hear there is a 12 word sentence you can speak to your partner... that will trigger deep feelings of love and instinctual attraction to you deep inside his chest?

    That's because deep inside these 12 words is a "secret signal" that fuels a man's impulse to love, idolize and look after you with his entire heart...

    12 Words Who Fuel A Man's Love Impulse

    This impulse is so built-in to a man's genetics that it will drive him to try better than before to do his best at looking after your relationship.

    As a matter of fact, fueling this mighty impulse is absolutely mandatory to getting the best possible relationship with your man that the moment you send your man one of the "Secret Signals"...

    ...You'll immediately find him expose his mind and soul to you in such a way he haven't expressed before and he'll distinguish you as the one and only woman in the world who has ever truly understood him.

    ReplyDelete

Post a Comment

Popular posts from this blog

Tenosynovial Giant Cell Tumors (TSGCTs) Market Research Report 2030 | Tenosynovial Giant Cell Tumors (TSGCTs) Market

Image
Tenosynovial Giant Cell Tumors   are a type of neoplasm that affects synovial-lined tendon sheaths, synovial joints, and surrounding soft tissue. Locally aggressive benign tissue lesions are defined by synovial lining inflammation in joints and tendons. Overexpression of the colony-stimulating factor 1 receptor is thought to cause these tumors to form. Giant cell tumors of the tendon sheath (GCTTS), pigmented villonodular tumors (PVNTS), extra-articular pigmented villonodular tumors of the tendon sheath, and localized or focal nodular synovitis are all terms used to describe TSGCTs. Tenosynovial Giant Cell Tumors Causes Translocation is an alteration to a chromosome that causes Tenosynovial Giant Cell Tumors. A chromosome segment breaks off and moves around. The cause of these translocations is unknown. The genetic code for making proteins is stored on chromosomes. A protein termed colony-stimulating factor 1 is produced in excess due to the translocation (CSF1). This protein attracts
Read more

Functional Dyspepsia Market Research Report 2030 | Functional Dyspepsia Market

Image
  Functional dyspepsia   is a term for recurring signs and symptoms of indigestion that have no apparent cause. Functional dyspepsia is also called non-ulcer stomach pain or non-ulcer dyspepsia. It's not clear what causes functional dyspepsia. Doctors consider it a functional disorder, which means that routine testing may not show any abnormalities. Hence, it is diagnosed based on symptoms. Functional Dyspepsia Signs and Symptoms  Functional dyspepsia is common and can be long-lasting — although signs and symptoms are mostly intermittent. These signs and symptoms resemble those of an ulcer, discomfort in your upper abdomen, often accompanied by bloating, belching, and nausea, An early feeling of fullness (satiety) when eating, Pain in the stomach that may sometimes occur unrelated to meals, or maybe relieved with meals. Functional Dyspepsia Epidemiology According to an article by Madisch et al. (2018), Functional Dyspepsia is one of the common functional disorders, with a prevalenc
Read more

Fibrodysplasia Ossificans Progressiva Market Research Report 2030 | Fibrodysplasia Ossificans Progressiva Market

Image
  Fibrodysplasia ossificans progressiva   is a disorder in which the skeleton, muscles, and connective tissues, such as tendons and ligaments, are replaced by bone (ossified). This position was to lead to the formation of the bones of the skeleton (extra-skeletal or heterotopic bone) that constrains movement. Fibrodysplasia ossificans progressiva Causes Fibrodysplasia ossificans progressiva is called a mutation in the ACVR1 gene. This gene is involved in bone growth and development. Mutations, and the possibility of a disorderly development. The gene can be inherited from a parent, but in most cases, the, is a new mutation, a person with a less-than-a family history of the disease. As a parent, they have a 50% chance of passing it on to their children. Fibrodysplasia ossificans progressiva Sign and Symptoms The  Fibrodysplasia ossificans progressiva  symptoms begin in the first decade of life with episodes of painful inflammatory soft tissue swellings. Gradually, there occurs restricti
Read more